Affordable Access

Access to the full text

Intralenticular Ozurdex® – One Year Later

Authors
  • Regan, Kathleen A.
  • Blake, Charles R.
  • Lukowski, Zachary L.
  • Iyer, Siva S.R.
Type
Published Article
Journal
Case Reports in Ophthalmology
Publisher
S. Karger AG
Publication Date
Dec 21, 2017
Volume
8
Issue
3
Pages
590–594
Identifiers
DOI: 10.1159/000485318
Source
Karger
Keywords
License
Green
External links

Abstract

Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.

Report this publication

Statistics

Seen <100 times